$URGN
UroGen Pharma Ltd. Stock $urgn

$urgn Overview Financials Valuation SEC Filings Company Website

2020 Q2 Form 10-Q Financial Statement

#000156459020038611 Filed on August 10, 2020

Income Statement

Concept	2020 Q2	2019 Q2	2019 Q1
Revenue	$372.0K	$18.00K	$0.00
YoY Change	1966.67%	-95.05%	-100.0%
Cost Of Revenue	$48.00K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Gross Profit	$324.0K	$18.00K	$0.00
YoY Change	1700.0%	-60.87%	-100.0%
Gross Profit Margin	87.1%	100.0%
Selling, General & Admin	$24.02M	$13.78M	$12.71M
YoY Change	74.36%	34.92%	109.34%
% of Gross Profit	7412.96%	76527.78%
Research & Development	$8.106M	$9.996M	$9.730M
YoY Change	-18.91%	20.83%	27.69%
% of Gross Profit	2501.85%	55533.33%
Depreciation & Amortization	$100.0K	$100.0K	$100.0K
YoY Change	0.0%	110.35%	-50.0%
% of Gross Profit	30.86%	555.56%
Operating Expenses	$32.12M	$23.77M	$22.43M
YoY Change	35.14%	28.63%	63.85%
Operating Profit	-$31.80M	-$23.75M	-$22.43M
YoY Change	33.88%	28.85%	64.46%
Interest Expense	$520.0K	$1.340M	$1.010M
YoY Change	-61.19%	226.83%	288.46%
% of Operating Profit
Other Income/Expense, Net	-$70.00K	-$70.00K	-$20.00K
YoY Change	0.0%
Pretax Income	-$31.35M	-$22.48M	-$21.44M
YoY Change	39.45%	24.68%	60.24%
Income Tax
% Of Pretax Income
Net Earnings	-$31.35M	-$22.48M	-$21.44M
YoY Change	39.47%	24.69%	60.25%
Net Earnings / Revenue	-8427.15%	-124872.22%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.441M	-$1.079M	-$1.109M
COMMON SHARES
Basic Shares Outstanding			20.48M
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q2	2019 Q2	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$125.1M	$189.2M	$246.7M
YoY Change	-33.87%	58.83%	93.49%
Cash & Equivalents	$37.57M	$90.42M	$246.7M
Short-Term Investments	$88.80M	$98.74M
Other Short-Term Assets	$3.300M	$2.000M	$1.600M
YoY Change	65.0%	66.67%	77.78%
Inventory	$1.125M
Prepaid Expenses
Receivables	$402.0K
Other Receivables	$0.00
Total Short-Term Assets	$129.9M	$191.2M	$248.3M
YoY Change	-32.06%	58.4%	92.93%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.401M	$909.0K	$929.0K
YoY Change	54.13%	29.86%	54.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$26.50M	$43.90M
YoY Change	-39.64%
Other Assets	$200.0K	$2.557M	$2.777M
YoY Change	-92.18%	2457.0%
Total Long-Term Assets	$31.20M	$47.37M	$3.757M
YoY Change	-34.14%	5821.5%	436.71%
TOTAL ASSETS
Total Short-Term Assets	$129.9M	$191.2M	$248.3M
Total Long-Term Assets	$31.20M	$47.37M	$3.757M
Total Assets	$161.1M	$238.6M	$252.1M
YoY Change	-32.47%	96.35%	94.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.598M	$2.101M	$1.700M
YoY Change	118.85%	-63.14%	-57.5%
Accrued Expenses	$11.80M	$9.700M	$8.600M
YoY Change	21.65%	340.91%	561.54%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$16.42M	$11.84M	$10.28M
YoY Change	38.66%	48.05%	86.85%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.000M	$1.900M	$2.200M
YoY Change	5.26%
Total Long-Term Liabilities	$2.000M	$1.943M	$2.184M
YoY Change	2.93%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.42M	$11.84M	$10.28M
Total Long-Term Liabilities	$2.000M	$1.943M	$2.184M
Total Liabilities	$18.42M	$13.79M	$12.46M
YoY Change	33.58%	72.34%	126.56%
SHAREHOLDERS EQUITY
Retained Earnings	-$297.2M	-$166.8M	-$144.3M
YoY Change	78.18%
Common Stock	$439.1M	$57.00K	$56.00K
YoY Change	770178.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$142.7M	$224.8M	$239.6M
YoY Change
Total Liabilities & Shareholders Equity	$161.1M	$238.6M	$252.1M
YoY Change	-32.48%	96.35%	94.79%

Cashflow Statement

Concept	2020 Q2	2019 Q2	2019 Q1
OPERATING ACTIVITIES
Net Income	-$31.35M	-$22.48M	-$21.44M
YoY Change	39.47%	24.69%	60.25%
Depreciation, Depletion And Amortization	$100.0K	$100.0K	$100.0K
YoY Change	0.0%	110.35%	-50.0%
Cash From Operating Activities	-$23.92M	-$14.56M	-$17.93M
YoY Change	64.29%	78.65%	86.35%
INVESTING ACTIVITIES
Capital Expenditures	-$280.0K	-$40.00K	$44.00K
YoY Change	600.0%	-69.23%	-38.89%
Acquisitions
YoY Change
Other Investing Activities	$17.80M	-$142.2M	$0.00
YoY Change	-112.52%	284200.0%	-100.0%
Cash From Investing Activities	$17.51M	-$142.2M	-$44.00K
YoY Change	-112.31%	78894.44%	-100.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$162.0M
YoY Change			152.08%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	16.30M	370.0K	163.5M
YoY Change	4305.41%	-1950.0%	154.46%
NET CHANGE
Cash From Operating Activities	-23.92M	-14.56M	-17.93M
Cash From Investing Activities	17.51M	-142.2M	-44.00K
Cash From Financing Activities	16.30M	370.0K	163.5M
Net Change In Cash	9.890M	-156.4M	145.5M
YoY Change	-106.32%	1772.81%	60.87%
FREE CASH FLOW
Cash From Operating Activities	-$23.92M	-$14.56M	-$17.93M
Capital Expenditures	-$280.0K	-$40.00K	$44.00K
Free Cash Flow	-$23.64M	-$14.52M	-$17.98M
YoY Change	62.81%	81.05%	85.42%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	402000
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q2	us-gaap	Inventory Net InventoryNet	1125000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3735000
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	523000
CY2020Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1476000
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	16423000
CY2020Q2	us-gaap	Liabilities Liabilities	18417000
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22001296
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22001296
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	60000
CY2020Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	438999000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	97389000
CY2020Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	1224000
CY2020Q2	us-gaap	Gross Profit GrossProfit	324000
CY2020Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	24018000
	us-gaap	Gross Profit GrossProfit	18000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24694000
	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2019Q4	us-gaap	Assets Assets	202388000
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	11186000
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6711000
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1585000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2604000
CY2019Q4	us-gaap	Liabilities Liabilities	22086000
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21026184
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21026184
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	57000
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	407986000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-228017000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	276000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	180302000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	202388000
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	372000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18000
CY2020Q2	us-gaap	Cost Of Revenue CostOfRevenue	48000
	us-gaap	Cost Of Revenue CostOfRevenue	48000
CY2019Q2	us-gaap	Gross Profit GrossProfit	18000
	us-gaap	Gross Profit GrossProfit	324000
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8106000
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9996000
CY2019Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13775000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	45991000
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-31800000
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-23753000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-70361000
CY2020Q2	urgn	Interest And Other Income Expenses Net InterestAndOtherIncomeExpensesNet	451000
CY2020Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	760000
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	142660000
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	161077000
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	224779000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	180302000
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	503000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14736000
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	15777000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	484000
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	us-gaap:OtherAssetsNoncurrent
CY2020Q2	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesCurrent
CY2020Q2	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	urgn:JelmytoMember
	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	urgn:JelmytoMember
CY2020Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	26499000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	48555000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	264000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19482000
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1994000
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-297159000
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	372000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19722000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26482000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-46186000
CY2019Q2	urgn	Interest And Other Income Expenses Net InterestAndOtherIncomeExpensesNet	1276000
	urgn	Interest And Other Income Expenses Net InterestAndOtherIncomeExpensesNet	1219000
	urgn	Interest And Other Income Expenses Net InterestAndOtherIncomeExpensesNet	2265000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	281000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-43640000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.19
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20095174
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	150454000
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	449000
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	142660000
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	239591000
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	172000
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7212000
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	281000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-22477000
	us-gaap	Net Income Loss NetIncomeLoss	-69142000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	90094000
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2219000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	484000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-68658000
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.44
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.08
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.22
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21753001
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20833671
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21454341
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	142660000
	us-gaap	Share Based Compensation ShareBasedCompensation	14736000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14659000
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	161447000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	281000
	us-gaap	Net Income Loss NetIncomeLoss	-43921000
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	224779000
	us-gaap	Net Income Loss NetIncomeLoss	-69142000
	us-gaap	Net Income Loss NetIncomeLoss	-43921000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	178000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	123000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-234000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	167000
	us-gaap	Share Based Compensation ShareBasedCompensation	14659000
	urgn	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	753000
	urgn	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	491000
	urgn	Operating Lease Liability Adjustments OperatingLeaseLiabilityAdjustments	748000
	urgn	Operating Lease Liability Adjustments OperatingLeaseLiabilityAdjustments	374000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1125000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	402000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1035000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1082000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2046000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-999000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-967000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1219000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-59564000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-32489000
	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	4000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	29688000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	142142000
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	60610000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	383000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	84000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	30539000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-142230000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	503000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2217000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	15885000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	161662000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16388000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	163879000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12637000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10840000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	50211000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	101571000
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	37574000
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	90731000
	urgn	Non Cash Purchase Of Property And Equipment NonCashPurchaseOfPropertyAndEquipment	219000
	urgn	Non Cash New Lease Liabilities NonCashNewLeaseLiabilities	29000
	urgn	Noncash Issuance Cost NoncashIssuanceCost	32000
	urgn	Non Cash Exercise Of Stock Options NonCashExerciseOfStockOptions	2000
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and marketable securities. The primary objectives for the Company<span style="color:#000000;">’</span>s investment portfolio are the preservation of capital and the maintenance of liquidity. The Company does not enter into any investment transaction for trading or speculative purposes.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company<span style="color:#000000;">’</span>s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s product sales are recognized through the Company's arrangement with a single customer, a third-party national specialty distributor. The Company assesses the need for an allowance for doubtful accounts primarily based on creditworthiness, historical payment experience and general economic conditions. The Company has not experienced any credit losses related to this customer and has not currently recognized any allowance for doubtful accounts.</p>
	us-gaap	Nature Of Operations NatureOfOperations	<p id="NOTE_1BUSINESS_NATURE_OPERATIONS" style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 1-BUSINESS AND NATURE OF OPERATIONS</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Nature of Operations</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UroGen<span style="letter-spacing:0.65pt;"> </span>Pharma<span style="letter-spacing:0.65pt;"> </span>Ltd.<span style="letter-spacing:0.4pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>an<span style="letter-spacing:0.25pt;"> </span>Israeli<span style="letter-spacing:0.5pt;"> </span>company<span style="letter-spacing:0.75pt;"> </span>incorporated<span style="letter-spacing:1pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>April<span style="letter-spacing:0.4pt;"> </span>20<span style="letter-spacing:-0.1pt;">0</span>4<span style="letter-spacing:0.45pt;"> </span>(“UPL”). </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UroGen<span style="letter-spacing:0.65pt;"> </span>Pharma<span style="letter-spacing:0.65pt;"> </span>Inc.,<span style="letter-spacing:0.35pt;"> </span>a<span style="letter-spacing:0.15pt;"> wholly owned </span>subsidiary<span style="letter-spacing:0.8pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>UPL,<span style="letter-spacing:0.45pt;"> </span>was<span style="letter-spacing:0.35pt;"> </span>incorporated<span style="letter-spacing:1pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>Del<span style="letter-spacing:-0.1pt;">a</span>ware<span style="letter-spacing:0.75pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>October<span style="letter-spacing:0.65pt;"> </span>2015<span style="letter-spacing:0.45pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>began<span style="letter-spacing:0.5pt;"> </span>operati<span style="letter-spacing:-0.1pt;">n</span>g<span style="letter-spacing:0.75pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>February<span style="letter-spacing:0.75pt;"> </span>2016<span style="letter-spacing:0.45pt;"> </span>(“UPI”). </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UPL<span style="letter-spacing:0.4pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>UPI<span style="letter-spacing:0.35pt;"> </span>(together<span style="letter-spacing:0.75pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>“Company”)<span style="letter-spacing:0.95pt;"> </span>is<span style="letter-spacing:0.15pt;"> </span>a<span style="letter-spacing:0.45pt;"> </span>bi<span style="letter-spacing:-0.1pt;">o</span>pharmaceutical<span style="letter-spacing:1.45pt;"> </span>company<span style="letter-spacing:0.75pt;"> </span>focused<span style="letter-spacing:0.65pt;"> </span>on<span style="letter-spacing:0.25pt;"> </span>deve<span style="letter-spacing:-0.1pt;">l</span>oping and commercializing<span style="letter-spacing:0.85pt;"> </span>novel<span style="letter-spacing:0.45pt;"> </span>therapies<span style="letter-spacing:0.75pt;"> </span>desi<span style="letter-spacing:-0.1pt;">g</span>ned<span style="letter-spacing:0.75pt;"> </span>to change<span style="letter-spacing:0.65pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>standard<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>care<span style="letter-spacing:0.4pt;"> </span>for<span style="letter-spacing:0.25pt;"> </span>urological<span style="letter-spacing:0.8pt;"> </span>pathologies. Since commencing operations, the Company has devoted substantially all of its efforts to securing intellectual property rights, performing research and development activities, including conducting clinical trials and manufacturing activities, hiring personnel, preparing for the commercial launch of our first commercial product, Jelmyto (mitomycin), formerly known as UGN-101, and our product candidate UGN-102, and raising capital to support and expand these activities. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 15, 2020, the U.S. Food and Drug Administration (“FDA”) granted expedited approval for Jelmyto (mitomycin), for pyelocalyceal solution, a first-in-class treatment indicated for adults with low-grade upper tract urothelial cancer (“LG-UTUC”). . Jelmyto consists of mitomycin, an established chemotherapy, and sterile hydrogel, using our proprietary sustained release RTGel technology. It has been designed to enable longer exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p>
	urgn	Entity Incorporation Date Of Incorporation Month And Year EntityIncorporationDateOfIncorporationMonthAndYear	2004-04
	urgn	Operations Commenced Date Month And Year OperationsCommencedDateMonthAndYear	2016-02
	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 2-BASIS OF PRESENTATION</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for fair statement of its financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. Interim results are not necessarily indicative of results for the full fiscal year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission (“SEC”) on March 2, 2020.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of UPL and its wholly owned subsidiary UPI. All material intercompany balances and transactions have been eliminated during consolidation.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has experienced net losses since its inception and has an accumulated deficit of $297.2 million and $228.0 million as of June 30, 2020 and December 31, 2019, respectively. The Company expects to incur losses and have negative net cash flows from operating activities as it continues its commercial launch of Jelmyto, and expands its portfolio and engages in further research and development activities, particularly conducting nonclinical studies and clinical trials.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of the Company depends on its ability to develop its technologies to the point of U.S. Food and Drug Administration (<span style="color:#000000;">“</span>FDA<span style="color:#000000;">”</span>) approval and subsequent revenue generation and, the Company must raise enough capital to finance these efforts. Based on management’s cash flow projections, the Company believes that its cash and cash equivalents and marketable securities are sufficient to fund the Company’s planned operations for at least the next 12 months. However, in the future, the Company may need to raise additional capital to finance the continued operating and capital requirements of the Company. There can be no assurances that the Company will be able to secure such additional financing, or if available, that it will be sufficient to meet its needs. If the Company cannot obtain adequate working capital, it may be forced to reevaluate its planned business operations.</p>
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-297200000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-228000000.0
	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:0.35pt;"> </span>preparation<span style="letter-spacing:0.9pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>financial<span style="letter-spacing:0.65pt;"> </span>statements<span style="letter-spacing:0.9pt;"> </span>in<span style="letter-spacing:0.2pt;"> </span>conformity<span style="letter-spacing:0.85pt;"> </span>with<span style="letter-spacing:0.35pt;"> </span>GAAP<span style="letter-spacing:0.5pt;"> </span>requires<span style="letter-spacing:0.65pt;"> </span>man<span style="letter-spacing:-0.1pt;">a</span>gement<span style="letter-spacing:1.05pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>make<span style="letter-spacing:0.45pt;"> </span>estimates<span style="letter-spacing:0.8pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>assumptions<span style="letter-spacing:1pt;"> </span>that<span style="letter-spacing:0.35pt;"> </span>affect the<span style="letter-spacing:0.05pt;"> </span>reported<span style="letter-spacing:0.7pt;"> </span>amounts<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>assets<span style="letter-spacing:0.6pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liabilities,<span style="letter-spacing:0.75pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>disclosure<span style="letter-spacing:0.8pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>cont<span style="letter-spacing:-0.1pt;">i</span>ngent<span style="letter-spacing:0.85pt;"> </span>assets<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>liabilities<span style="letter-spacing:0.7pt;"> </span>at<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>date<span style="letter-spacing:0.4pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>financ<span style="letter-spacing:-0.1pt;">i</span>al<span style="letter-spacing:0.65pt;"> </span>statements<span style="letter-spacing:0.9pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>the reported<span style="letter-spacing:0.7pt;"> </span>amounts<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>revenues<span style="letter-spacing:0.75pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>expenses<span style="letter-spacing:0.8pt;"> </span>duri<span style="letter-spacing:-0.1pt;">n</span>g<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>reporting<span style="letter-spacing:0.7pt;"> </span>period.<span style="letter-spacing:0.55pt;"> </span>Actual<span style="letter-spacing:0.5pt;"> </span>results<span style="letter-spacing:0.55pt;"> </span>may<span style="letter-spacing:0.35pt;"> </span>differ<span style="letter-spacing:0.45pt;"> </span>from<span style="letter-spacing:0.4pt;"> </span>those<span style="letter-spacing:0.45pt;"> </span>estimates.<span style="letter-spacing:0.8pt;"> </span>As<span style="letter-spacing:0.25pt;"> </span>applicable<span style="letter-spacing:0.9pt;"> </span>to the unaudited condensed<span style="letter-spacing:0.45pt;"> </span>consolidated<span style="letter-spacing:1pt;"> </span>financi<span style="letter-spacing:-0.1pt;">a</span>l<span style="letter-spacing:0.65pt;"> </span>statements,<span style="letter-spacing:0.95pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>most<span style="letter-spacing:0.4pt;"> </span>significant<span style="letter-spacing:0.8pt;"> </span>estimates<span style="letter-spacing:0.8pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>assumptions<span style="letter-spacing:1pt;"> </span>relate<span style="letter-spacing:0.45pt;"> </span>to<span style="letter-spacing:0.2pt;"> </span>the<span style="letter-spacing:0.3pt;"> </span>fair<span style="letter-spacing:0.3pt;"> </span>value<span style="letter-spacing:0.45pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>share-based<span style="letter-spacing:1pt;"> </span>compensat<span style="letter-spacing:-0.1pt;">i</span>on<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.35pt;"> </span>measurement<span style="letter-spacing:0.5pt;"> </span>of<span style="letter-spacing:0.2pt;"> </span>revenue.</p>
CY2020Q2	urgn	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	151600000
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4598000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4694000
CY2020Q2	urgn	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	409000
CY2019Q4	urgn	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	399000
CY2020Q2	urgn	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	1358000
CY2019Q4	urgn	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	2644000
CY2020Q2	urgn	Accrued Selling General And Administrative Expense Current AccruedSellingGeneralAndAdministrativeExpenseCurrent	2240000
CY2019Q4	urgn	Accrued Selling General And Administrative Expense Current AccruedSellingGeneralAndAdministrativeExpenseCurrent	2767000
CY2020Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	598000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	682000
CY2020Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9203000
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	11186000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1331000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2353000
	urgn	Other Finance Expenses Income OtherFinanceExpensesIncome	-112000
	urgn	Other Finance Expenses Income OtherFinanceExpensesIncome	-88000
	urgn	Finance Income Expense Net FinanceIncomeExpenseNet	1219000
	urgn	Finance Income Expense Net FinanceIncomeExpenseNet	2265000
CY2020Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	893000
CY2020Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	232000
CY2020Q2	us-gaap	Inventory Net InventoryNet	1125000
CY2020Q2	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2020Q2	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2020Q2	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2020Q2	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2020Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	135470000
CY2020Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	760000
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	136230000
CY2020Q2	us-gaap	Interest Receivable InterestReceivable	500000
CY2020Q2	urgn	Debt Securities Available For Sale Unrealized Gain Position DebtSecuritiesAvailableForSaleUnrealizedGainPosition	800000
CY2020Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	17600000
CY2020Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	10
	us-gaap	Other Than Temporary Impairment Loss Debt Securities Portion Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings	0
CY2020Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	109732000
CY2019Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	114386000
CY2020Q2	urgn	Available For Sale Securities Debt Maturities After One Through Three Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue	26498000
CY2019Q4	urgn	Available For Sale Securities Debt Maturities After One Through Three Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue	48556000
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	136230000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	162942000
CY2020Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2574000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1975000
CY2020Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1173000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	998000
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1401000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	977000
CY2020Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	200000
CY2019Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000
	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	UPL signed an addendum to its November 2014 lease agreement for the Company’s executive offices located in Israel, in order to increase the office space rented and to extend the rent period until 2019. In March 2019, UPL utilized the agreement extension option and extended the rent period for additional three years until August 2022.
CY2020Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P3Y
	urgn	Lessee Operating Lease Extended Lease Expiration Date Month And Year LesseeOperatingLeaseExtendedLeaseExpirationDateMonthAndYear	2022-08
CY2020Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	428000
	us-gaap	Operating Lease Cost OperatingLeaseCost	858000
CY2020Q2	us-gaap	Sublease Income SubleaseIncome	56000
	us-gaap	Sublease Income SubleaseIncome	112000
CY2020Q2	us-gaap	Variable Lease Cost VariableLeaseCost	30000
	us-gaap	Variable Lease Cost VariableLeaseCost	86000
CY2020Q2	us-gaap	Lease Cost LeaseCost	402000
	us-gaap	Lease Cost LeaseCost	832000
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3011000
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1994000
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1476000
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0
	us-gaap	Operating Lease Payments OperatingLeasePayments	849000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	90000
CY2020Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y6M18D
CY2020Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0545
CY2020Q2	urgn	Lessee Operating Sub Lease Payments To Be Received Remainder Of Fiscal Year LesseeOperatingSubLeasePaymentsToBeReceivedRemainderOfFiscalYear	61000
CY2020Q2	urgn	Lessee Operating Sub Lease Payments To Be Received Two Years LesseeOperatingSubLeasePaymentsToBeReceivedTwoYears	235000
CY2020Q2	urgn	Lessee Operating Sub Lease Payments To Be Received Three Years LesseeOperatingSubLeasePaymentsToBeReceivedThreeYears	243000
CY2020Q2	urgn	Lessee Operating Sub Lease Payments To Be Received Four Years LesseeOperatingSubLeasePaymentsToBeReceivedFourYears	251000
CY2020Q2	urgn	Lessee Operating Sub Lease Payments To Be Received Five Years LesseeOperatingSubLeasePaymentsToBeReceivedFiveYears	49000
CY2020Q2	urgn	Lessee Operating Sub Lease Payments To Be Received LesseeOperatingSubLeasePaymentsToBeReceived	839000
CY2020Q2	urgn	Lessee Operating Sub Lease Income From Fixed Lease Payments LesseeOperatingSubLeaseIncomeFromFixedLeasePayments	56000
	urgn	Lessee Operating Sub Lease Income From Fixed Lease Payments LesseeOperatingSubLeaseIncomeFromFixedLeasePayments	112000
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	372000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	372000
	urgn	Payment On License Agreement Milestone In Acquired In Process Research And Development Expenses PaymentOnLicenseAgreementMilestoneInAcquiredInProcessResearchAndDevelopmentExpenses	10000000.0
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000.0
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000.0
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22000000.0
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22000000.0
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21000000.0
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21000000.0
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7212000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14736000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14659000
CY2020Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	42300000
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y9M25D

Files In Submission

Name	View Source	Status
0001564590-20-038611-index-headers.html	Edgar Link	pending
0001564590-20-038611-index.html	Edgar Link	pending
0001564590-20-038611.txt	Edgar Link	pending
0001564590-20-038611-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
urgn-10q_20200630.htm	Edgar Link	pending
urgn-10q_20200630_htm.xml	Edgar Link	completed
urgn-20200630.xsd	Edgar Link	pending
urgn-20200630_cal.xml	Edgar Link	unprocessable
urgn-20200630_def.xml	Edgar Link	unprocessable
urgn-20200630_lab.xml	Edgar Link	unprocessable
urgn-20200630_pre.xml	Edgar Link	unprocessable
urgn-ex311_8.htm	Edgar Link	pending
urgn-ex312_6.htm	Edgar Link	pending
urgn-ex321_7.htm	Edgar Link	pending
urgn-ex322_9.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$URGN
UroGen Pharma Ltd. Stock $urgn

2020 Q2 Form 10-Q Financial Statement

#000156459020038611 Filed on August 10, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$URGN UroGen Pharma Ltd. Stock $urgn

2020 Q2 Form 10-Q Financial Statement

#000156459020038611 Filed on August 10, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$URGN
UroGen Pharma Ltd. Stock $urgn